More news – Page 11
-
NewsLilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal
The deal brings it access to oral therapies targeting inflammatory-mediated conditions, including cardiometabolic, neurodegenerative and autoimmune diseases.
-
News
Amgen acquires UK cancer biotech Dark Blue Therapeutics for $840m
Gains access to the company’s small molecule-targeted protein degraders to expand its oncology pipeline.
-
News
US oral GLP-1 first as Novo Nordisk launches Wegovy pill
The obesity drug’s new formulation gains an important opportunity to define the market before regulators finish assessing Lilly’s rival orforglipron.
-
NewsSamsung gains first US manufacturing site through $280m GSK deal
The CDMO will acquire the pharma company’s Human Genome Sciences facility in Maryland.
-
NewsGeneric manufacturer safety records revealed by new consumer app
News organisation ProPublica’s Rx Inspector tool connects FDA information on factory location and regulatory records to individual generic drugs.
-
NewsAlnylam invests $250m to boost RNAi manufacturing in the US
Will add its enzymatic ligation platform, now accepted on the FDA’s emerging technology programme, to its Norton, Massachusetts site.
-
NewsChitose and Fujifilm Biosciences sign biopharma manufacturing alliance
The deal will see the companies combine their respective work on CHO-MK cells and GMP-manufactured culture media.
-
NewsNovartis chromatography study shows downstream purification benefits
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
-
NewsJ&J’s Rybrevant-Lazcluze combination wins FDA first in lung cancer
US approval of the subcutaneous therapy provides a novel chemotherapy-free frontline option in EGFR-mutated NSCLC.
-
NewsEurope makes progress in its bid to tackle medicine shortages
And as the Critical Medicines Act advances, so too does the Biotech Act, with the moves attracting mixed support from the region’s pharma industry.
-
NewsBicycle Therapeutics strikes uranium deal for sustainable radiopharmaceuticals
UK biotech commits to scale up of 228Th extraction and a long-term supply agreement to facilitate production of thousands of doses of 212Pb for cancer therapies annually.
-
NewsAstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval
FDA approval of the drug in combination with Perjeta initiates a $150 million milestone payment to Daiichi Sankyo from AstraZeneca under their joint collaboration.
-
NewsGaelic Labs boosts its beta lactam manufacturing with Athlone deal
The move consolidates Ireland’s two leading producers of the antibiotics.
-
NewsAI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential
New phase I data suggests the oral small molecule ASC50 could help address immunology conditions such as psoriasis.
-
NewsCHMP recommends cancer medicines by SFL Pharmaceuticals and Serum Life Science Europe
The EMA’s human medicines committee also recommended approval of drugs by GSK, Moderna, STADA, Lupin Europe and Cytokinetics.
-
NewsNanexa collaboration to enhance Moderna’s mRNA drug delivery
Moderna’s $500 million deal with Nanexa will focus on improving long-acting injectable drug delivery, potentially improving mRNA medicines.
-
NewsOff-the-shelf dual-antibody immunotherapy shows myeloma potential
The combination of two J&J biologics demonstrates a significantly improved treatment response for the most aggressive form of multiple myeloma in new phase II data.
-
NewsThermo Fisher Scientific expands its bioprocessing capabilities in Asia
Investments in India, Korea and Singapore aim to reinforce its support for the region’s biopharma sector.
-
NewsEurope edges closer to formalising new ‘Pharma package’ industry rules
Progress made in the region’s approach to critical medicines and antibiotics as the EU Council and EU Parliament agree a new deal.
-
NewsLilly to establish third new US manufacturing facility in Alabama
Announcement of Eli Lilly and Company's fourth new US manufacturing plant is expected within the next few weeks.